ALLK - allakos.com Debt to Book Capitalization Ratio

Graphic logo of Allakos (ALLK)

Allakos Inc. relies on automated biomarker analysis to accelerate research. The company's current debt-to-capitalization ratio on the main GURU.Markets chart shows a value of 0.00. Its pre-revenue status makes the balance sheet dependent on liquidity, while high R&D costs and the anticipation of GI antibody test results create significant risks for capital.

ALLK (Allakos) Debt to Book Value history from 07/04/2022 to 05/24/2025
Core merchandise of allakos.com

For Allakos Inc., which is developing therapies for rare inflammatory diseases, managing the debt load is critical when scaling clinical trials. This metric compares total liabilities to the company's total equity, measuring the degree of reliance on borrowed funds. Analyzing the ratio of liabilities to book capitalization allows for an assessment of financial stability and insolvency risk. A downward trend in this curve indicates deleveraging. An optimal balance between leverage and equity ensures the investment attractiveness of the business.

Who Allakos Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Immunome Corp - Debts to Book Capitalization|GOSS: Debts to Book Capitalization|KalVista Pharmaceuticals (KALV) - Debt to Book Capitalization Ratio|SEPN (septerna.com) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.|Debt to Book Capitalization Ratio Savara Inc|Debts to Book Capitalization RIGL|Debts to Book Capitalization ANAB (AnaptysBio Inc.)|Debt to Book Capitalization Ratio ATXS (Astria Therapeutics)|engene.com - Debts to Book Capitalization|RAPT (RAPT Therapeutics, Inc.) - Debt to Book Capitalization Ratio|JBIO: Debts to Book Value|Aclaris - Debt to Book Capitalization Ratio|Debts to Net Assets Kyverna Therapeutics, Inc|TLSA - Debt to Book Value|Debt to Net Assets Ratio cabalettabio.com|VTYX (Ventyx Biosciences, Inc.) - Debts to Book Capitalization|Debts to Net Assets THTX (Theratechnologies, Inc.)|AVTX - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Eledon Pharmaceuticals, Inc ELDN|AGEN: Debts to Book Capitalization|climbbio.com (CLYM) - Debt to Book Value|Zura Bio Limited - Debt to Book Value|aTyr Pharma Inc (ATYR) - Debts to Net Assets|ADAG (Adagene Inc) - Debts to Book Capitalization|Debts to Book Capitalization IMA|Debt to Book Capitalization Ratio Shattuck Labs, Inc. (STTK)|Debt to Book Capitalization Ratio EQ (equilliumbio.com)|Debt to Book Capitalization Ratio Connect Biopharma Holdings Limited CNTB|Immunic Therapeutics - Debt to Book Capitalization Ratio|Atara Biotherapeutics Inc - Debt to Book Capitalization Ratio|IFRX: Debts to Book Capitalization|Debt to Book Capitalization Ratio X4 Pharmaceuticals (XFOR)|Adicet Bio, Inc. (ACET) - Debts to Book Capitalization Ratio|CELU - Debts to Book Capitalization|Debt to Net Assets Ratio INmune Bio Inc|Debts to Book Capitalization BRNS|Debts to Book Capitalization KZR (Kezar Life Sciences Inc)|Debt to Book Capitalization Ratio SAB Biotherapeutics|akaritx.com - Debt to Net Assets Ratio|ENLV: Debt to Book Capitalization Ratio|QTTB - Debt to Book Value|GOVX: Debts to Book Capitalization|Debts to Book Capitalization Edesa Biotech Corp|IBIO - Debt to Book Value|Debt to Net Assets Ratio Carisma Tx|XTLB (XTL Biopharmaceuticals Ltd.) - Debts to Book Capitalization|Debts to Net Assets BOLT (boltbio.com)|HCW Biologics - Debt to Book Capitalization Ratio|Aptevo Therapeutics, Inc. - Debt to Book Value|AIM: Debt to Book Capitalization Ratio|Aditxt (ADTX) - Debt to Book Value|GRI: Debt to Book Value|XRTX (XORTX Therapeutics Inc) - Debts to Book Capitalization|Debt to Book Capitalization Ratio ReShape Lifesciences (HIND)|Debt to Book Value Ratio Revelation Biosciences Corp|Indaptus Therapeutics - Debts to Book Capitalization|Debts to Book Value scinai.com (SCNI)|Debts to Book Capitalization CALI (CalciMedica)|Affimed NV - Debts to Book Capitalization|HOOK - Debt to Book Capitalization Ratio|IGMS: Debt to Book Capitalization Ratio|iTeos Therapeutics (ITOS) - Debt to Book Capitalization Ratio|oceanbiomedical.com (OCEA) - Debt to Book Capitalization Ratio|TCBP (TC BioPharm) - Debts to Book Capitalization|Debts to Book Capitalization THRD